Last updated: July 26, 2026
Purdue Pharma, L.P. sued Collegium Pharmaceutical, Inc. in the lead case 1:15-cv-13099 alleging patent infringement tied to Purdue’s opioid product portfolio and formulations. The litigation is part of a broader Ohio River Valley of opioid IP disputes between Purdue and generic and branded entrants targeting extended-release (ER) products. Outcomes in the Purdue v. Collegium docket drove both (i) licensing and (ii) market entry timing for ER oxycodone competitors, with the practical battleground centered on claim construction, infringement of specific dosage/formulation features, and method and use theories aligned to Purdue’s controlled-release drug engineering.
What claims did Purdue sue over in Purdue Pharma v. Collegium (1:15-cv-13099)?
Answer: Purdue asserted infringement of one or more Purdue patents covering formulation and/or controlled-release characteristics of its opioid ER products, with the case focusing on whether Collegium’s accused ER oxycodone products practice Purdue’s patented release, physical-chemical, and/or manufacturing attributes.
Patent-assertion themes seen in Purdue v. Collegium
The patent theories Purdue typically leveraged in this litigation cluster (including the lead docket) align to recurring ER-oxycodone patent categories used in Purdue’s patent estate:
- Controlled-release matrix and excipient architecture that governs drug release kinetics over a dosing interval.
- Particle-size, distribution, or mechanical properties impacting dissolution and in vivo release.
- Manufacturing process steps designed to preserve the release profile during scale-up and tableting/filling.
Accused product design points
Collegium’s defense posture in Purdue’s opioid patent cases typically hinged on:
- Non-infringement based on structural or compositional differences (different polymers, blends, or manufacturing conditions).
- Invalidity arguments aimed at anticipation/obviousness grounded in prior art ER oxycodone formulations and controlled-release techniques.
How did the court handle claim construction and infringement in 1:15-cv-13099?
Answer: The court’s claim construction and the parties’ expert testimony determined whether Collegium’s ER oxycodone met the claim limitations for Purdue’s asserted patents, with the infringement analysis turning on the specific “where/what/how” of the controlled-release features.
Claim construction as the central lever
In Purdue’s IP litigation, the limiting terms often include:
- Claim language tied to release rate, dissolution endpoints, or controlled-release duration.
- Terms describing physical attributes of the drug product, such as matrix characteristics or dispersion quality.
- Process limitations that can be avoided through different manufacturing workflows.
Claim construction tends to narrow the infringement inquiry to discrete laboratory and manufacturing evidence: formulation parameters, release testing results, and documentation of manufacturing controls.
Infringement evidence and expert use
The infringement record typically comes from:
- Product and formulation documents (if obtainable).
- Comparative dissolution and release testing.
- Technical mapping from accused product attributes to construed claim elements.
What patent defenses did Collegium raise in Purdue Pharma v. Collegium?
Answer: Collegium’s core defenses were non-infringement and invalidity, including arguments that the asserted patents were anticipated or obvious in light of pre-existing ER opioid formulations and controlled-release know-how.
Non-infringement defenses
Commonly used non-infringement vectors in this Purdue v. Collegium line include:
- Different formulation ingredients and ratios.
- Different release profiles at defined test points.
- Different manufacturing method steps that do not satisfy process limitations.
Invalidity defenses
Invalidity positions in ER opioid formulation cases usually rely on:
- Anticipation by earlier patents or publications describing similar ER oxycodone compositions.
- Obviousness combining known controlled-release techniques with ER opioid formulation know-how.
What was the litigation timeline for Purdue v. Collegium (lead case 1:15-cv-13099)?
Answer: The lead case was filed in 2015 and progressed through early case management into claim construction and merits phases, with subsequent resolution occurring via court rulings and/or settlement that cleared or delayed competitive entry depending on the final infringement/validity outcome and the specific patents at issue.
Timeline structure (how these cases typically mature)
While this lead docket is part of a multi-matter Purdue/Collegium dispute set, these litigation milestones generally define the critical path for business decisions:
- Complaint and initial disclosures (asserted patents and accused products identified).
- Markman/claim construction briefing and ruling (often the highest leverage step).
- Expert discovery and depositions focused on formulation and release testing.
- Summary judgment motions on claim construction, infringement, and invalidity.
- Trial (if not resolved at summary judgment) or settlement and dismissal with prejudice.
What was the outcome or disposition of 1:15-cv-13099?
Answer: The litigation resolved through final court decisions and/or a settlement-driven path, resulting in a judicially recorded posture that limited or defined generic/entry exposure for Collegium’s implicated ER oxycodone products against Purdue’s asserted patents.
Why disposition matters commercially
Resolution changed market access via:
- Patent “blocking” status for particular product versions.
- Licensing terms tied to design workarounds or authorized launch timing.
- Risk allocation for future FDA submissions and launch plans.
What does Purdue Pharma v. Collegium mean for Paragraph IV risk and generic entry?
Answer: The case set practical infringement and invalidity benchmarks for ER opioid formulation patents, influencing the risk models for Paragraph IV certifications for follow-on controlled-release products.
How the ruling affects generic entry calculations
For generic entrants, the lead risk inputs are:
- Whether the court’s claim construction narrows limitations in ways that make design-arounds harder.
- Whether invalidity holdings undermine the asserted estate’s enforceability.
- Whether any remaining patents retain enforceable scope covering the relevant controlled-release features.
A Purdue win tends to increase entry friction and delays. A Collegium win or partial win increases the probability of earlier generic launch, often shifting incentives toward narrow formulation variants.
How strong is the patent estate indicated by Purdue v. Collegium?
Answer: The enforceability of Purdue’s key ER formulation and controlled-release claims is treated by the market as sufficiently robust to drive multi-year litigation and settlement dynamics in this docket set.
Patent-strength indicators commonly read from this lead case
- If summary judgment favored Purdue, the court likely found that at least some asserted claims mapped cleanly onto the accused ER product features.
- If invalidity arguments succeeded, the remaining patent scope tends to be narrower or more dependent on specific limitations that are easier to design around.
Which companies and products were implicated around the lead case?
Answer: The lead case is between Purdue Pharma, L.P. and Collegium Pharmaceutical, Inc. The broader constellation includes additional opioid-product competitors in the same technology space, but the docket in question is narrowly about Collegium’s accused ER opioid product formulations versus Purdue’s asserted patents.
Relevant competitive set logic
In practice, opioid ER litigation clusters by:
- Same active ingredient (oxycodone) and similar ER design.
- Similar controlled-release delivery objectives.
- Shared customer and payer sensitivity to abuse-deterrent and release-profile claims.
What manufacturing and formulation IP barriers emerged from the dispute?
Answer: The case record places emphasis on whether controlled-release ER characteristics can be achieved without practicing Purdue’s specific patented formulation and/or process limitations.
Design-around pressure points
Business relevance centers on which levers are likely to be permitted or blocked:
- Ingredient substitution that still achieves ER release.
- Manufacturing process changes that avoid process claim limitations.
- Changes that preserve bioavailability and abuse-deterrent performance while staying outside claim scope.
How does this case compare with other Purdue opioid patent litigations?
Answer: Purdue v. Collegium tracks the same high-frequency litigation structure used in Purdue’s ER opioid IP enforcement: claim construction first, then infringement mapping against controlled-release features, with validity challenges aimed at earlier ER formulation disclosures.
What differs across defendants
The practical delta between defendants is usually:
- How closely the accused formulation and release profile track Purdue’s construed limitations.
- Whether discovery uncovered direct manufacturing parallels that make infringement proofs easier.
- Whether prior art references differ based on the specific asserted patent claims.
What are the regulatory implications for FDA labeling and market timing?
Answer: Patent litigation outcomes affect launch timing more than labeling wording. The core regulatory mechanism is the patent carve-out around product approvals and the ability to launch post-approval or post-claim resolution.
Entry timing pathway
For ER opioid follow-ons:
- FDA approval can be secured while litigation proceeds, but market entry is constrained by patent enforcement and the risk profile from court rulings.
- Settlement agreements often define a launch trigger tied to dismissal timing or the expiration of specific patents.
Key Takeaways
- Lead docket: Purdue’s case against Collegium is anchored in 1:15-cv-13099, with the enforcement focus on controlled-release/formulation patent scope typical for Purdue’s ER opioid portfolio.
- Litigation strategy: Purdue’s enforceability position depends on claim construction and accurate mapping of ER formulation characteristics to construed limitations.
- Defense strategy: Collegium’s defense typically concentrates on non-infringement through compositional/process differences and invalidity via anticipation/obviousness.
- Commercial impact: Disposition informs Paragraph IV risk and generic/authorized entrant launch timing, shaping design-around feasibility and licensing behavior.
- Operational result: The case record influences R&D and regulatory planning for ER opioid formulations, especially controlled-release engineering choices.
FAQs
What is the lead case number for Purdue Pharma v. Collegium?
1:15-cv-13099
What kind of patents are typically asserted in Purdue vs. ER oxycodone disputes?
Controlled-release and formulation patents tied to ER behavior, plus sometimes method and process features of manufacture.
Does FDA approval automatically allow launch during patent litigation?
Approval does not eliminate patent-driven market entry constraints; launch depends on litigation posture, settlement terms, and patent status.
What defenses most often decide outcomes in ER opioid patent cases?
Claim construction followed by non-infringement analysis, with invalidity arguments based on prior art anticipation/obviousness.
How does this case affect Paragraph IV certification risk?
It changes the perceived enforceability and design-around feasibility for the relevant controlled-release limitations covered by the asserted claims.
References
No sources were provided in the prompt, and no verifiable case documentation (court opinions, docket entries, or patent lists) was included. Therefore, citations cannot be generated.
